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ARTICLE OPEN
The rumen microbiome: an underexplored resource for novel
antimicrobial discovery
Linda B. Oyama1, Susan E. Girdwood1, Alan R. Cookson1, Narcis Fernandez-Fuentes 1, Florence Privé1, Hannah E. Vallin1,
Toby J. Wilkinson1, Peter N. Golyshin 2, Olga V. Golyshina2, Ralf Mikut 3, Kai Hilpert4, Jennifer Richards5, Mandy Wootton5,
Joan E. Edwards6, Marc Maresca7, Josette Perrier7, Fionnuala T. Lundy8, Yu Luo8, Mei Zhou9, Matthias Hess10, Hilario C. Mantovani11,
Christopher J. Creevey1 and Sharon A. Huws12
Antimicrobial peptides (AMPs) are promising drug candidates to target multi-drug resistant bacteria. The rumen microbiome
presents an underexplored resource for the discovery of novel microbial enzymes and metabolites, including AMPs. Using
functional screening and computational approaches, we identiﬁed 181 potentially novel AMPs from a rumen bacterial
metagenome. Here, we show that three of the selected AMPs (Lynronne-1, Lynronne-2 and Lynronne-3) were effective against
numerous bacterial pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). No decrease in MRSA susceptibility
was observed after 25 days of sub-lethal exposure to these AMPs. The AMPs bound preferentially to bacterial membrane lipids and
induced membrane permeability leading to cytoplasmic leakage. Topical administration of Lynronne-1 (10% w/v) to a mouse model
of MRSA wound infection elicited a signiﬁcant reduction in bacterial counts, which was comparable to treatment with 2%
mupirocin ointment. Our ﬁndings indicate that the rumen microbiome may provide viable alternative antimicrobials for future
therapeutic application.
npj Bioﬁlms and Microbiomes  (2017) 3:33 ; doi:10.1038/s41522-017-0042-1
INTRODUCTION
The global increase of multi-drug resistant (MDR) bacteria,
combined with the decreasing number of novel and effective
antibacterial agents being developed for the market, poses a
serious global threat to human health.1,2 Urgency is required with
respect to discovery and development of novel antibiotics,
alongside antimicrobial stewardship and development of rapid
tools to detect MDR bacteria.3 Antimicrobial peptides (AMPs),
particularly cationic AMPs, are promising alternatives to currently
available antibiotics, due to their broad spectrum activity against
Gram positive and Gram negative bacteria, and their rapid mode
of action on the cytoplasmic membrane, which results in a
decreased rate of resistance being developed by the targeted
pathogens. However, synthetic generation of AMPs has produced
very few if any viable AMPs for medical use, thus there is a need to
further prospect from nature.4
Depending on availability of resources, bacteria in communities
can either be symbiotic with one another or live in competition.5
In order to compete, bacteria often up-regulate genes encoding
AMPs to kill other bacteria in the community.5 The rumen is an
example of such a highly competitive community with a very
complex microbiome, composed of unique and diverse range of
bacteria, archaea, protozoa, fungi, and viruses6,7 and as such is a
potentially unique resource for novel AMP discovery.8–10 In the
past few years, it has become apparent that culture dependent
methods to evaluate microbial populations substantially under-
estimates the diversity of microorganisms present, and only
around 10–20% of the species from the rumen environment have
been cultured to date.11,12 The limitations surrounding culturability
and antimicrobial discovery can be circumvented using sequence
and functional-based metagenomics, which allow mining of whole
microbiomes for novel bioactive compounds.13,14
Here, we report the discovery and characterization of three
AMPs (i.e., Lynronne-1, Lynronne-2 and Lynronne-3) via functional
metagenomic screening of a rumen bacterial metagenomic library
and in-silico sequence data analysis. These novel AMPs from the
rumen microbiome have the potential to treat MDR bacterial
infections.
RESULTS
Identiﬁcation of AMPs
A metagenomic library consisting of 8448 fosmids from the plant-
attached rumen microbiome15 was screened for antimicrobial activity
by a combination of agar-based functional screening, sequencing of
positive clones and bioinformatic prediction of AMP sequences. To
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test the antimicrobial activity of fosmid clones, lawns of pathogens
including methicillin-sensitive Staphylococcus aureus (MSSA) RN4220,
Escherichia coli K12, Salmonella enterica serovar Typhimurium SL1344,
Listeria monocytogenes NCTC 11994 (serovar 4b) and Enterococcus
faecalis JH2-2 were inoculated on appropriate agar medium and the
clones were gently transferred on top using multichannel pin
replicators. After an incubation period of 24 h at the appropriate
temperatures, 255 fosmids produced clearing zones in the pathogen
lawn, indicating that the metagenome clones carried inserts with
antimicrobial activity. Of these clones, twenty-four were selected
randomly and sequenced using the GS FLX system. A summary of the
assembly metrics of the twenty-four metagenomic inserts with
antimicrobial activity is provided in Supplementary Table S1. The full
fosmid sequences are available in the GenBank database under the
BioProject PRJNA264884; BioSample IDs: SAMN063330279 to
SAMN063330302. Prediction of AMPs from the identiﬁed open
reading frames (ORFs) yielded a total of 181 AMPs. A peptide library
consisting of 135 of these AMPs (≤25 amino acids (AAs)) was
synthesized and screened for antimicrobial activity using the SPOT
technique (synthesis of large numbers of peptides on marked spots
on cellulose membrane sheets allowing for subsequent highthrough-
put screening).16 Twenty-ﬁve active AMPs were identiﬁed in this
screen (Supplementary Table S2). Candidates, Lynronne-1 (19 AAs:
LPRRNRWSKIWKKVVTVFS-NH2), Lynronne-2 (20 AAs: HLRRINKLLTRI-
GLYRHAFG-NH2) and Lynronne-3 (20 AAs: NRFTARFRRTPWR
LCLQFRQ-NH2) encoded in fosmid clones SABPL29H11, SABPL5A1
and SABPL12(2)A3, respectively and were selected for further analysis
due to their broad spectrum antibacterial activity and lower minimum
inhibitory concentration (MIC) values. The nucleotide and protein
sequences of the ORFs from which they were derived are available in
the GenBank database under accession numbers KY628802,
KY628803 and KY628804, respectively. Sequences upstream and
downstream of these ORFs are shown in Supplementary Fig. S1. The
likely producers of Lynronne-1, Lynronne-2 and Lynronne-3 were
identiﬁed as Prevotella ruminicola 23 (CP002006.1), Uncultured
bacterium Contig939 (KC246977.1) and Uncultured bacterium Con-
tigcl_1559 genomic sequence (KC246861.1) respectively (Supplemen-
tary Table S3 and Supplementary Fig. S2). Structural modelling using
PEP-FOLD17 indicate that these peptides adopt a α-helical conforma-
tion of amphipathic nature, an arrangement typical of many α-helical
AMPs18 (Fig. 1). The AMPs have a net positive charge of +6, +5 and
+6, respectively with a hydrophobicity ratio of ≥40%.
Antimicrobial activity, resistance and mechanism of action
The antibacterial activity of Lynronne-1, Lynronne-2 and
Lynronne-3 against twenty-nine clinically important multidrug-
resistant pathogens was explored. All three peptides had
promising activity against Gram-positive pathogens, including
MDR strains (Table 1). Lynronne-1 had an MIC range of 8–32,
Lynronne-2: 32–256 and Lynronne-3: 32–128 of µg/ml for
methicillin-resistant S. aureus (MRSA) strains. Since cationic
peptides rarely demonstrate high in vitro antimicrobial activities
seen with some conventional antibiotics, the MICs determined for
Lynronne-1, Lynronne-2 and Lynronne-3 were not surprising and
fall within the range of many commercially available AMPs.19,20
Lynronne-1, Lynronne-2 and Lynronne-3 (at 3× MIC) had
relatively faster bactericidal activity against three MRSA strains
when compared to vancomycin, a ﬁrst line drug for MRSA (Fig. 2a,
and Supplementary Fig. S3a, b). Reductions of >8 log10 CFU/ml
occurred within the ﬁrst 10 min for Lynronne-1 and Lynronne-3,
and >3 log10 CFU/ml in 30 min for Lynronne-2 (Fig. 2a, and
Supplementary Fig. S3a, b). Vancomycin at 3× MIC produced
between 1 to >4 log10 CFU/ml reductions depending on the MRSA
strain. This can be attributed to difference in kill kinetics and mode
of action.21 Time dependent killing of E. coli K12 was investigated
to ascertain the efﬁcacy of the peptides against Gram-negative
bacterial strains. All three AMPs caused a rapid decrease in E. coli
K12 viability at 3× MIC with complete cell death occurring within
10min (see Supplementary Fig. S4a). Control agents, Polymyxin B
and ciproﬂoxacin showed expected bactericidal activities22 (>4
log10 CFU/ml) against E. coli K12 at 10 min and 3 h, respectively
(see Supplementary Fig. S4a).
Serial passage of MRSA strains in the presence of sub-MIC levels
of Lynronne-1, Lynronne-2 and Lynronne-3 over a period of
25 days failed to produce mutants that were resistant to the AMPs
(Fig. 2b and Supplementary Fig. S3c, d), suggesting a non-speciﬁc
mode of action.23 The efﬁcacy of Lynronne-1, Lynronne-2 and
Lynronne-3 against S. aureus bioﬁlm attachment and established
bioﬁlms at sub and supra-MIC concentrations were tested. MRSA
ATCC 33591 strain was used in this assay as it was a better bioﬁlm
former in our hands than the other strains (results not shown). All
AMPs decreased bioﬁlm attachment at 2× MIC concentrations
(Fig. 2c) and Lynronne-2 was effective even at 0.25× MIC (data not
shown). Anti-bioﬁlm activity against established bioﬁlms was
observed with all peptides at ≥2× MIC concentrations (Fig. 2c).
Importantly, Lynronne-1, Lynronne-2 and Lynronne-3 also
showed little haemolytic activity against red blood cells (Fig. 2d).
Similarly, Lynronne-1, Lynronne-2 and Lynronne-3 were less
cytotoxic to mammalian HUVEC and HepG2 cells when compared
Fig. 1 Predicted structures for peptides: Lynronne-1, Lynronne-2
and Lynronne-3. a Lynronne-1, b Lynronne-2 and c Lynronne-3.
Main-chain and side chains depicted in ribbon and stick representa-
tion respectively and colored according to atom type: carbon,
oxygen and nitrogen in green, red and blue respective. Two
orientations are shown rotated about the shown axis. Ct and Nt (C
and N terminals) as well as selected residues are depicted in the
ﬁgure. Figures were rendered using PyMol
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to the positive control agent, Staurosporine, which had 50%
growth inhibition (GI50), total growth inhibition (TGI) and 50%
lethal concentration (LC50) of 0.00047, 0.0047 and 0.014 µg/ml
respectively. Lynronne-2 had no cytotoxic activity against
mammalian HUVEC and HepG2 cells at the highest concentration
tested (128 µg/ml) while Lynronne-3 had little cytotoxicity at
concentration close to the MIC with GI50, TGI and LC50 of 24.4, 61.2
and >128 µg/ml respectively. Lynronne-1 on the other hand, had
low toxicity at concentrations above the MIC with GI50, TGI and
LC50 of 45.9, 67.1 and 98.1 µg/ml respectively. Whereas Lynronne-
1 and 3 were able to permeabilize MRSA USA300 cell membrane,
very little permeabilization activity was observed for Lynronne-2
even at >3 times its MIC concentration (Fig. 3a and Supplementary
Fig. S5a), demonstrating that although antimicrobial activity of
Lynronne-1 and 3 is due to pore formation, mechanism of action
of Lynronne-2 may be different. In accordance with cytotoxicity
results, Lynronne-1, Lynronne-2 and Lynronne-3 were less able to
permeabilize eukaryotic membranes (Hep2G) compared to
bacterial cell membranes (Supplementary Fig. S5b).
Since bacterial membrane permeabilization was demonstrated
by the newly identiﬁed AMPs, we used lipid monolayer (Langmuir
balance) to narrow down the potential lipids that are targeted by
Table 1. Minimum Inhibitory Concentrations (MICs) against drug-resistant pathogens
Organism information Peptides and comparator antibiotics (µg/ml)
Lab no./Strain ID Organism Resistances Cip/Lev (L) L-1 L-2 L-3 P4 P5 P8 P10 P11 P12 P15a P15s Van Mup
EMRSA-15 S. aureus MRSA, Cip >256 32 32 32 128 64 64 250 250 250 128 2
ATCC 33591 S. aureus MRSA 16 128 64 2
USA300 BAA-1717 S. aureus MRSA 8 256 64 2 0.12
Q14-0320 S. aureus MRSA 64 32 >128 128 >128 >128 >128 >128 64 64 >128 >128
Q14-0325 S. aureus MRSA 0.25 32 >128 128 >128 128 128 >128 32 64 >128 64
Q14-0352 S. aureus MRSA 0.5 32 >128 128 >128 >128 128 >128 32 64 >128 >128
Q14-0390 S. aureus MRSA 64 32 >128 128 >128 128 128 >128 32 64 >128 >128
NCTC 12493 S. aureus MRSA 0.25 16 64 64 32 64 32 >128 32 16 >128 64
ATCC 29213 S. aureus Sensitive 0.25 32 >128 128 >128 128 128 >128 32 64 >128 >128
RN4220 S. aureus Sensitive >256 32 32 32 128 64 64 256 256 256 128 1
Q14-0095 K. pneumoniae KPC 16 32 >128 32 >128 128 >128 >128 >128 >128 >128 128
Q14-0146 K. pneumoniae OXA-48 >128 32 64 64 >128 >128 >128 >128 >128 >128 >128 128
Q14-0285 K. pneumoniae VIM 32 16 64 64 64 128 128 >128 >128 >128 >128 128
Q14-0251 K. pneumoniae CTX-M 16 16 64 64 >128 >128 >128 >128 128 128 >128 128
ATCC 700603 K. pneumoniae SHV-18 0.25 16 64 32 128 >128 128 >128 128 64 >128 128
NCTC 13442 K. pneumoniae OXA-48 1 16 128 32 >128 128 >128 >128 128 >128 >128 128
K. pneumoniae Sensitive 0.03 16 128 32 >128 >128 >128 >128 128 >128 >128 >128
Q13-0717 A. baumanii IMI, MER 16 4 8 32 >128 32 64 >128 64 64 >128 128
Q13-0795 A. baumanii IMI, MER 16 4 8 32 >128 32 64 >128 64 64 128 64
1560739339 A. baumanii OXA-23 128 4 16 32 >128 128 64 >128 128 64 128 128
Q12-0809 A. baumanii OXA-23, OXA-51 128 4 8 16 32 64 32 64 128 32 128 128
Q12-0867 A. baumanii Sensitive 0.25 4 8 8 64 16 64 128 32 16 128 64
Q14-0208 P. aeruginosa (CF) CAZ, IMI, MER 4 16 32 32 >128 128 64 >128 64 64 128 128
Q14-0890 P. aeruginosa (CF) CAZ, IMI, MER 4 32 64 16 64 64 32 128 16 32 128 64
Q12-0535 P. aeruginosa (CF) Sensitive 0.06 64 128 128 >128 128 128 125 128 32 128 128
Q12-0581 P. aeruginosa (CF) IMI, MER 2 32 128 32 128 64 128 >128 32 128 128 64
Q12-0758 P. aeruginosa (CF) CAZ, IMI, MER 2 32 64 32 128 128 128 >128 32 128 128 64
ATCC 27853 P. aeruginosa (CF) Sensitive 0.25 64 >128 128 >128 128 >128 >128 >128 128 128 128
PA01 P. aeruginosa (CF) 0.5 32 128 32 512 64 32 512 512 512 128
AMT0060 P. aeruginosa (CF) 0.06 (L) 32 64 128 >512 64
C3719 P. aeruginosa (CF) < 0.03 (L) 64 32 16 >512 32
LESB58 P. aeruginosa (CF) 0.06 (L) 64 256 32 >512 128
M15U114296A C. coli Cip, Tet, Ery, Amox, Gent >128 64 >128 128 >128 128 >128 >128 >128 >128 128 128
M15U114452A C. coli Cip, Cla, Ery >128 64 >128 128 >128 128 >128 >128 >128 >128 128 128
M16U109179A C. jejuni Azith, Cip, Ery, Tet >128 64 >128 128 >128 128 >128 >128 >128 >128 128 128
M16U109568A C. jejuni Cip 128 64 >128 64 >128 128 >128 >128 >128 >128 128 128
NCTC 11351 C. jejuni 64 >128 128 >128 128 >128 >128 >128 >128 128 128
NCTC 11161 C. jejuni 0.5 4 32 256
ATCC 33292 C. jejuni 0.12 4 32 64
K12 E. coli 0.06 32 64 64 64 64 64 256 256 256 64 128
SL1344 Sal. typhimurium 0.12 32 32 64 32 64 32 64 512 256 128 256
JH2-2 Ent. faecalis 64 32 32 64 64 64 64 512 256 256 128 64
NCTC 11994 List. monocytogenes 64 32 32 32 64 64 64 512 256 128 128 64
Blank: not tested
L-1, L-2 and L-3 Lynronne-1, 2 and 3, P4-P15a: peptides 4–15a, Lev (L) Levoﬂoxacin, Cip Ciproﬂoxacin, Van Vancomycin, Mup Mupirocin, KPC Klebsiella
pneumoniae carbapenemase, OXA Oxacillin, VIM Metallo-β-Lactamase gene, CTX-M extended spectrum β-Lactamase, SHV-18 β-Lactamase, IMI (imipenem), MER
(meropenem), CAZ (ceftazidime), Tet Tetracycline, Ery Erythromycin, Amox Amoxicillin, Gent Gentamicin, Azith Azithromycin, Cla Clarithromycin
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these peptides. The use of MRSA lipid extract demonstrated a
higher insertion ability of Lynronne-1 and Lynronne-3 compared
to Lynronne-2 (Fig. 3b) and is in agreement with bacteria
membrane permeabilization. The use of pure lipids demonstrated
that Lynronne-1, Lynronne-2 and Lynronne-3 preferentially inter-
act with lipids speciﬁc to bacteria, including 1-palmitoyl-2-oleoyl-
sn-glycero-3-(phospho-rac-(1-glycerol)) (POPG), cardiolipin, lipotei-
choic acid (LTA) or phosphatidylethanolamine (POPE) (also
present in the inner membrane leaﬂet of eukaryotes) above lipids
only present in eukaryotes, such as palmitoyloleoylphosphatidyl-
choline (POPC) (Fig. 3c and Supplementary Fig. S5c, d). This may
explain the limited haemolytic and cytotoxic activity against
mammalian cells in spite of their antibacterial activity. Interest-
ingly, Lynronne-2 showed the highest afﬁnity for LTA demon-
strated by measurement of the critical pressure of insertion of the
peptides in the different lipids (Supplementary Fig. S5d), suggest-
ing that this peptide could target other molecules containing
teichoic acid moieties, including cell wall teichoic acids and may
also explain its antimicrobial activity in the absence of pore-
formation in whole bacteria. Transmission electron micrographs of
cells treated with Lynronne-1, Lynronne-2 and Lynronne-3 (at 3×
MICs for 1 h) reveal varying changes in cell morphology and some
cytoplasmic leakage (Fig. 4 and Supplementary Fig. S4b). MRSA
USA300 cells treated with Lynronne-2 showed very little
morphology changes, corresponding to the low permeabilization
activity of the peptide. Further investigation into events leading
up to changes in cell morphology may be required as the
transmission electron microscopic analysis is semi-quantitative.
In vivo efﬁcacy
Given the promising in vitro activity of Lynronne-1, Lynronne-2
and Lynronne-3, we investigated their in vivo therapeutic
potential within a murine model of MRSA skin infection.24 Topical
administrations of Lynronne-1 (2% w/v), in a group of mice with
MRSA infected wounds (ﬁve mice/group) once daily for 3 days was
associated with a signiﬁcant decrease (P < 0.01) in the colony
count relative to the control group treated with phosphate-
buffered saline (PBS, pH 7.4) (Fig. 5a). However, this decrease was
less than a 2-log reduction (≥99%) in colony counts. No signiﬁcant
decreases in colony counts were observed in the animal groups
treated with Lynronne-2 (2% w/v) and Lynronne-3 (2% w/v). The
reference, 2% mupirocin ointment (Dermasafe® Ointment) was
associated with a signiﬁcant reduction (>2-log reduction, and P <
0.001) in bacterial counts, consistent with historical data.24 Given
this promising in vivo result for Lynronne-1, we further tested its
efﬁcacy at a higher dose (10% w/v) in the wound model.
Lynronne-1 at 10% (w/v) was associated with a signiﬁcant (99%)
reduction in bacterial density (≥2-log reduction, and P < 0.001)
and comparable to mupirocin (2%) treatment (Fig. 5b). These
ﬁndings suggest that Lynronne-1 can effectively reduce the
bacterial load in MRSA infected wounds.
The efﬁcacy of Lynronne-1, Lynronne-2 and Lynronne-3 were
subsequently tested in a murine model of MRSA deep thigh
infection.25 The maximum tolerable dose of all three AMPs was
predetermined to be 10mg/kg in vivo in mice. Test animals were
inoculated intramuscularly (IM) in the right thigh with 0.1 ml/thigh
of S. aureus MRSA ATCC 33591 (inoculum size of 1.57 × 105 CFU/
Fig. 2 Antimicrobial activity and haemolytic activity of Lynronne-1, Lynronne-2 and Lynronne-3. a Time-dependent kill of MRSA USA300 by
antimicrobial compounds at 3× MIC concentration. Dashed lines indicate limit of detection. b Resistance acquisition during serial passaging of
MRSA USA300 cells in the presence of sub-MIC levels of antimicrobials. The y axis is the fold change in MIC during passaging. For mupirocin,
256× MIC was the highest concentration tested. The ﬁgure is representative of three independent experiments. c Quantiﬁcation of anti-bioﬁlm
activity (MRSA 33591): * and ** P< 0.05 and 0.01 respectively—signiﬁcantly different from untreated cells (positive). d Haemolytic activity,
dashed line indicates 50% haemolysis. Values from at least three independent replicates; error bars represent the standard deviation)
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mouse) followed by treatment with Lynronne-1, Lynronne-2 and
Lynronne-3 and the comparator antibiotic, vancomycin. Intrave-
nous (IV) administrations of Lynronne-1, Lynronne-2 and
Lynronne-3 at 10 mg/kg once or twice (2 h or 2 and 8 h post
infection) were not associated with any signiﬁcant antimicrobial
effects compared to the vehicle/control group (0.9% NaCl).
Vancomycin administered twice at 30 mg/kg IV) elicited a
signiﬁcant reduction (≥99%, 2-log reduction in CFU/g and
P < 0.001). However, vancomycin at 10 mg/kg IV (administered
twice) only elicited a signiﬁcant reduction (P < 0.001) but not a 2-
log reduction in colony counts compared to the control group
(Fig. 5c).
Upon testing for stability of peptides, we observed that
Lynronne-1 rapidly degraded in the presence of serum with only
48 and 15% of the parent peptide remaining after 2 h and 6 h
respectively. Lynronne-2 and Lynronne-3 were relatively more
stable with ≥60 and 42%, as well as ≥88 and 34% after 2 h and 6 h
respectively (Fig. 3d). A similar pattern was observed when these
peptides were treated with trypsin (Supplementary Fig. S6), a
common feature among peptides that are susceptible to
degradation by peptidases.26 This susceptibility to degradation
may explain the poor efﬁcacy of the peptides when administered
intravenously.
DISCUSSION
AMPs are promising candidates for overcoming the critical and
growing challenge of bacterial resistance to currently utilized
antibiotics. The high cost and low success rate associated with the
identiﬁcation of novel and affective AMPs from natural sources
has hindered the search for novel AMPs in the past. This hurdle
has been overcome by new technological advances and
improvements in traditional recombinant methods.23 Using a
combination of functional metagenomics and computational
approaches, we were able to show that the rumen microbiome
is a promising resource for bio-prospecting novel AMPs, and these
three peptides (Lynronne-1, Lynronne-2 and Lynronne-3), identi-
ﬁed in this study are potential therapeutic candidates.
Lynronne-1, Lynronne-2 and Lynronne-3 are efﬁcacious against
clinically important drug-resistant pathogens in in vitro models of
infection. In addition, Lynronne-1 decreased bacterial counts in
MRSA wound infections using a murine model, similar to
commercially used mupirocin ointment, suggesting that it could
be used topically in the treatment of MDR bacterial infections.
Lynronne 1, 2 and 3 displayed low haemolytic activity against
blood cells and negligible cytotoxicity against mammalian cells.
Results presented here suggest that loss of cell viability after
exposure to Lynronne-1, Lynronne-2 and Lynronne-3 among
many factors is due to membrane permeabilization, which
contributes to membrane disruption and leakage of cell content.
In addition to their broad antibacterial spectrum, selectivity and
rapid killing of bacterial cells, Lynronne-1, Lynronne-2 and
Lynronne-3 also showed a low tendency to select for resistance
in the bacteria strains tested. The antimicrobial compounds
discovered here are novel and demonstrate potent activity
against clinically relevant human pathogens, rendering them as
potential therapeutics. The identiﬁcation of these novel AMPs
support the hypothesis that the rumen is a promising resource for
the discovery of novel antimicrobials with clinical relevance.
Fig. 3 Mode of action studies of Lynronne-1, Lynronne-2 and Lynronne-3 against MRSA: a Membrane permeabilization activity against MRSA
USA300 measured by propidium iodide assay at 10min. b Dose-dependent interaction of peptides with total MRSA lipid extract, the initial
surface pressure of lipid monolayer being 30 ± 0.5 mN/m. c Interaction of peptides (at 1 µg/ml ﬁnal concentration) with pure lipids-maximal
variation of surface pressure induced by the injection of peptide in lipid monolayer with initial surface pressure of 30± 0.5 mN/m. d peptide
stability/degradation in 25% serum over time. Relative peptide concentrations were determined by integration of the peaks from RP-HPLC
chromatograms (values from three independent replicates; error bars represent one standard deviation)
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METHODS
Functional antimicrobial activity screening of a rumen
metagenomic library
A metagenomic library consisting of 8448 clones from a plant-associated
rumen microbiome was prepared previously.15 The clones were transferred
gently using multichannel pin replicators (Molecular Devices Ltd, Berkshire
UK) onto Luria–Bertani agar plates containing a lawn (500 µl) of S. aureus
(MSSA) RN4220, E. coli K12, Salmonella enterica serovar Typhimurium
SL1344, E. faecalis JH2-2 and L. monocytogenes NCTC 11994 serovar 4b
(OD600 = 1) using sterile pin replicators. Plates containing these pathogens
were incubated at 37 °C (or 30 °C for L. monocytogenes) for 24 h, and
clearing zones around the fosmid clones were considered as indicative of
clones containing gene inserts coding for antimicrobial compounds.
Assays were performed in sextuplicates to ensure reproducibility.
Sequence-based screening of putative antimicrobial positive
fosmid clones
Fosmids with putative antimicrobial activity were sequenced using the
Genome Sequencer FLX platform (454 Life Sciences) according to
manufacturer guidelines. Following sequence assembly using the default
parameters on the gsAssembler software v.2.5.3 (Roche Life Sciences),
sequences were trimmed and vector sequence were removed using
BioEdit (version 7.1.11).27 VecScreen on NCBI was used to search the
sequences for vector contamination. ORFs were determined using NCBI’s
ORF ﬁnder on the NCBI blast suite (v2.2.28).28
In silico identiﬁcation of AMPs
Prediction of AMP sequences within the identiﬁed ORFs was achieved
using a variety of software available at various public databases.
Speciﬁcally, we used the antimicrobial peptide database,29 the Antimicro-
bial Sequence Scanning System (AMPA),30 BACTIBASE,31 collection of anti-
microbial peptides (CAMP),18,32 and antibacterial peptides (AntiBP).33 Only
ORFs that were predicted to encode putative AMPs within at least two of
the utilized databases were explored further. The active sites within
positive ORFs were predicted using AMPA30 and make up the peptides
included in the peptide library to be screened for antimicrobial activity.
Peptide synthesis and antimicrobial screening
The peptides in the created peptide library were synthesized based on the
SPOT technique and pure peptides (≥95% purity) were synthesized on
resin using solid phase Fmoc peptide chemistry.16 The 135 peptides in the
peptide library were screened for antimicrobial activity using both
luminescent (Pseudomonas aeruginosa strain H1001)34 and non-
luminescent (epidemic methicillin resistant S. aureus EMRSA-15, Sal.
typhimurium and E. coli K12) bacterial strains. Activity against non-
luminescent bacteria strains was assessed by ﬂuorescence readings
(excitation/emission spectra of 560/590 nm) after the addition of resazurin
dye (100 µm ﬁnal concentration). The results from the screen were
analysed using the MATLAB extension Gait-CAD as previously described.35
Concentration values with a 75% reduction of luminescence or ﬂuores-
cence (IC75) in relation to untreated controls were computed. Three
peptide activity classes: active (IC75≤ 0.25), semi-active (0.25 < IC75≤ 0.50)
and inactive IC75 > 0.5 were assigned against all microorganisms.
Determination of MIC
MICs were determined using a modiﬁed broth microdilution method36 in
cation adjusted Mueller Hinton broth (MHB) following the International
Organization for Standardization 20776-1 standard for MIC testing with a
ﬁnal bacterial inoculum concentration of 5 × 105 CFU/ml.37 Peptides
dissolved in sterile distilled water and comparator antibiotics dissolved
in the appropriate solvents38 were added to sterile U-bottom polypropy-
lene 96-well microplates at desired concentrations. MIC was deﬁned as the
lowest concentration of peptide or antibiotic, which inhibited the visible
growth of bacteria after 18–24 h incubation at appropriate temperatures.
Time kill kinetics
Assessment of the bactericidal activity of peptides and comparator
antibiotics was performed as previously described39 using exponential-
phase cultures of pathogens grown in MHB (1 × 108–10 CFU/ml). Peptides
were added at concentrations 3 times their MIC values. Experiments were
performed in quadruplicates, and CFU/ml was calculated at different time
points after over overnight incubation.
Fig. 4 Transmission electron micrographs of MRSA cells. Representative micrographs of untreated and peptide treated MRSA cells. Cells were
treated at 3× MIC peptide concentration for 1 h. Scale bars are 200 or 500 nm as shown on micrographs
Antimicrobial properties of rumen microbiome
LB Oyama et al.
6
npj Biofilms and Microbiomes (2017)  33 Published in partnership with Nanyang Technological University
Selection for AMP resistance
To evaluate if populations of AMP-resistant bacteria could be selected,
cultures were continuously exposed to Lynronne-1, Lynronne-2 and
Lynronne-3 for a duration of 25 days, as previously described.40 Brieﬂy,
broth microdilution susceptibility testing was performed using a standard
doubling-dilution series of Lynronne-1, Lynronne-2 and Lynronne-3
concentrations on day 1. Following incubation of the cultures for 24 h,
and determination of the MIC, the well that contained the highest
concentration of AMPs permitting growth was diluted 1:1000 in MHB and
used to provide the inoculum for the next MIC assay; this process was
repeated daily for 25 days.
Erythrocyte leakage assay
The haemolytic activity of peptides was determined by measuring
haemoglobin leakage from human and sheep erythrocytes (Divbioscience,
NL) after 1 h incubation at OD450nm. Cetyltrimethylammonium bromide
(CTAB), a non-speciﬁc detergent was also included as a positive control.
Triton-X 100 (0.1% v/v) was also used as an indicator of 100% haemolysis
while PBS treatment represented auto-haemolysis.
Cytotoxicity of peptides
Cytotoxic activity of the identiﬁed peptides was determined using HUVEC
and HEPG2 cells as described previously.41,42 Three dose response
parameters 50% growth inhibition (GI50), total growth inhibition (TGI)
and 50% lethal concentration (LC50) were calculated for each experimental
agent and cellular tumor assay results are presented as the percent cell
growth or percent tube length of speciﬁc activity. Signiﬁcant responses
were deﬁned when observed cell growth was ≤50% and tube length was
≤70% using the proliferation and tube formation assays respectively.
Permeabilization of eukaryotic membrane by Lynronne-1, Lynronne-2 and
Lynronne-3 was also investigated using HepG2 cells as described
previously.43
Membrane permeabilization and peptide-lipid interactions
Membrane permeabilsation was evaluated using propidium iodide assay
as previously explained,43 with CTAB as positive control. Peptide–lipid
interaction was measured using reconstituted lipid monolayer.44 Total lipid
extract from overnight liquid cultures of MRSA USA300 was obtained by
Folch extraction, resuspended in chloroform and stored at −20 °C under
nitrogen conditions. Pure bacterial and eukaryotic lipids, POPG, cardiolipin,
LTA, POPE and POPC (Avanti Polar Lipid USA) were reconstituted in
chloroform at 1 mg/ml and stored at −20 °C under nitrogen. Using a 50 µl
Hamilton’s syringe, total MRSA lipid extract or pure lipids were spread at
the surface of PBS creating a lipid monolayer at the air-water interface until
an initial surface pressure of 30 ± 0.5 mN/m was reached. This corresponds
to a lipid packing density theoretically equivalent to that of the outer
leaﬂet of the cell membrane.45 After 5–10min of incubation allowing
evaporation of the solvent and stabilization of the initial surface pressure,
peptides were injected into the PBS (pH 7.4, volume 800 µl) sub-phase
using a 10 µl Hamilton syringe. The variation of the surface pressure caused
by peptide injection was then continuously monitored using a fully
automated microtensiometer (µTROUGH SX, Kibron Inc., Helsinki, Finland)
until reaching equilibrium (maximal surface pressure increase usually
obtained after 15–25min). Critical pressure of insertion of each peptide in
the different lipids was also determined by changing the initial pressure of
lipid monolayer (from 10 and 30 mN/m) and measuring the variation of
pressure caused by the injection of peptide (at 1 µg/ml ﬁnal concentra-
tion). All experiments were carried out in a controlled atmosphere at 20 °C
± 1 °C and data were analyzed using the Filmware 2.5 program (Kibron Inc.,
Helsinki, Finland). Variation of surface pressure was plotted as a function of
initial surface pressure and critical pressure of insertion was calculated as
the theoretical value of initial pressure of lipid monolayer not permissive to
peptide insertion, i.e., a variation of pressure equal to 0 mN/m. The
accuracy of the system under our experimental conditions was determined
to be ± 0.25 mNm/1 for surface pressure measurements.
Fig. 5 In vivo efﬁcacy in mouse models of infection. a Efﬁcacy of Lynronne-1, Lynronne-2, Lynronne-3 and mupirocin against methicillin
resistant S. aureus, USA300 MRSA (BAA-1717), wound infection in, ICR mice. Inoculum = 1.05 × 105 CFU/ml. b Efﬁcacy of Lynronne-1 and
mupirocin against methicillin resistant S. aureus, USA300 MRSA (BAA-1717). c Efﬁcacy of intravenously administered Lynronne-1, Lynronne-2,
Lynronne-3 and Vancomycin in the S. aureus (ATCC 33591) MRSA thigh infection model with neutropenic male ICR mice. Inoculum = 1.57 × 105
CFU/ml, ×1 (administered once at 2 h) or ×2 (twice at 2 and 8 h post infection). *, **, *** Signiﬁcant difference (P< 0.05, 0.01 and 0.001,
respectively) compared to the control group (PBS or 0.9% NaCl) was determined by one-way ANOVA followed by the use of a Dunnett’s test
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Serum stability and trypsin degradation assays
The stability of Lynronne-1, Lynronne-2 and Lynronne-3 in the presence of
serum was investigated by monitoring the concentrations of the remaining
soluble peptides by reverse phase high-performance liquid chromatogra-
phy (RP-HPLC), as described previously by Nguyen and colleagues.26
Degradation of Lynronne-1, Lynronne-2 and Lynronne-3 in the presence of
trypsin was adapted from a previously described method.46 Brieﬂy, trypsin
(5 µl of 0.5 ng/ml) and 37.5 µl trypsin activation buffer (50 mM Tris, 2 mM
CaCl2, pH 7.8-8) was added to 7.5 µl of 5 mg/ml Lynronne-1, Lynronne-2
and Lynronne-3 and incubated at 37 °C for different time points (0, 1, 3,
and 24 h). An aliquot from each reaction mixture at 0 h was prepared to
allow matrix-assisted laser desorption/ionization time-of-ﬂight (MALDI-
TOF) mass spectrometric veriﬁcation of the synthetic peptides prior to
incubation. Trypsin action buffer (5 µl) and peptides without trypsin was
used as negative control. After the various incubation times, the reaction
mixtures were acidiﬁed by addition of an equal volume (50 µl) of 10% (v/v)
triﬂuroacetic acid (TFA) to stop further enzyme activity. Lynronne-1,
Lynronne-2 and Lynronne-3 degradation products were evaporated to
dryness and reconstituted in acetonitrile/water/TFA (40/59.5/0.5%, v/v/v).
Samples (1 µl) were carefully placed onto a stainless steel (MALDI) target,
covered with 1 µl of matrix (53 mM a-cyano-4-hydroxycinnamic acid in
acetonitrile/water/TFA, 70/29.97/0.03%, v/v/v) solution before analysis by
mass spectrometry.
Molecular modelling of AMP 3D structures
The modelling of the 3D conformation of peptides was carried out using
the de novo structural prediction method PEP-FOLD.17 The best 3D models
for each peptide was selected according to PEP-FOLD score, based on the
OPEP force ﬁeld.47 Results were visualized using the PyMOL v1.7.6
program.48
Transmission electron microscopy
Effects of AMPs on bacterial cell morphology was investigated using
transmission electron microscopy as described by Huws et al.49 Bacterial
cultures in mid-log phase were treated with Lynronne-1, Lynronne-2 and
Lynronne-3 (at 3× MIC for 1 h) and then ﬁxed with 2.5% (v/v)
glutaraldehyde. Cells were post-ﬁxed with 1% osmium tetroxide (w/v),
stained with 2% (w/v) uranyl acetate and Reynold’s lead citrate and
observed using a JEOL JEM1010 transmission electron microscope (JEOL
Ltd, Tokyo, Japan) at 80 kV.
Quantiﬁcation of anti-bioﬁlm activity
The effectiveness of Lynronne-1, Lynronne-2, and Lynronne-3 to prevent
(a) bioﬁlm attachment and (b) disrupt established bioﬁlms was measured
using a 96-well bioﬁlm model.50 Brieﬂy, MRSA cultures grown in brain heart
infusion (BHI) broth were washed, resuspended to an OD600nm = 0.02 in BHI
broth and (a) treated with peptides (at 1/4×, 1/2×, 1×, 2× and 4× MIC) and
incubated at 37 °C for 24 h or (b) incubated at 37 °C for 24 h to allow
establishment of bioﬁlms, washed in PBS to remove planktonic cells, and
further incubated with peptides (at 1/4×, 1/2×, 1×, 2× and 4× MIC) in fresh
BHI broth at 37 °C for 24 h. The bioﬁlms were washed in PBS to remove
planktonic cells, ﬁxed with methanol, stained with 0.5% (w/v) crystal violet
and re-solubilized with 33% (v/v) acetic acid. The optical density of bioﬁlms
was measured at 570 nm.
In vivo efﬁcacy of peptides in mouse models of MRSA skin and
thigh infections
The efﬁcacy of Lynronne-1, Lynronne-2 and Lynronne-3 for treating a
wound infection caused by USA300 community-associated methicillin
resistant S. aureus (MRSA, strain BAA-1717) was evaluated using a murine
wound model with ICR mice.24 A sharp punch (ID 12mm) was used to
create excisional skin wounds in groups of ﬁve female ICR mice (5–6 weeks
old). The mice were inoculated topically on the wound area (5 µl per
wound) with 1.05 × 105 CFU/mouse of strain BAA-1717 suspended in 5 µl
PBS. Peptides (2 or 10% w/v) in PBS (pH 7.4), control (PBS), and mupirocin
2% (Dermasafe® ointment) were topically applied (20 µl/mouse) directly to
wounds 2 h post infection and once daily thereafter for three consecutive
days. Test animals were sacriﬁced and the wound tissue was excised for
enumeration of bacteria cells (CFU/wound). A two-log reduction in the
bacterial count (≥99% reduction) relative to the control group indicates
signiﬁcant activity. Statistical signiﬁcance (P < 0.05) was performed with
one-way analysis of variance (ANOVA) followed by use of the Dunnett’s
method.
In the thigh infection model, using neutropenic mice,25 groups of ﬁve
male ICR mice weighing 22 ± 2 g were inoculated intramuscularly (IM)
with S. aureus MRSA, ATCC 33591 (1.57 × 105 CFU/mouse (0.1 ml/thigh)) in
the right thigh. Lynronne-1, Lynronne-2 and Lynronne-3 at 10mg/kg were
intravenously (IV) administered once 2 h post infection or twice 2 and 8 h
post-infection. The reference substance, vancomycin, was also intrave-
nously injected 2 and 8 h post-infection at 10 and 30mg/kg. Test animals
were sacriﬁced 26 h after inoculation and the infected thighs were excised
and the bacterial burden (CFU/gram) was determined.
Data availability
The datasets generated and/or analysed during the current study are
available under the study name (SRP099633 Cow rumen Metagenome) in
the GenBank database, (https://www.ncbi.nlm.nih.gov/).
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